This week, cardiac monitoring firm AngelMed announced its new name; Tempus nabbed FDA approval for its tumor profiling test; and iRhythm revealed that it’s been subpoenaed by the US Department of Justice.

Q3 medtech financing doubled in dollar volume to $3 billion, with debt offerings again representing the majority of the aggregate; acquisitions totaled $5.3 billion, mainly due to Johnson & Johnson’s $4.3 billion buy of Abbott Medical Optics. Diagnostics financings, which brought in $85 million, continued to decline, but at $5 billion, acquisitions showed a slight increase over the previous quarter, with Danaher’s takeover of Cepheid accounting for most of the M&A volume.

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.